A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-04-25
Adverse events
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 97); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-23 (study day 102); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 250); relationship: N; serious criteria: hospitalization
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-02-07 (study day 270); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-10 (study day 454); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-03 (study day 600); relationship: Y
Data queries
No data queries.